Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Raw Materials: 2016-2024

Historic Raw Materials for Adma Biologics (ADMA) over the last 8 years, with Dec 2024 value amounting to $60.5 million.

  • Adma Biologics' Raw Materials rose 58.99% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 58.99%. This contributed to the annual value of $60.5 million for FY2024, which is 14.10% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Raw Materials is $60.5 million, which was up 14.10% from $53.0 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Raw Materials ranged from a high of $60.5 million in FY2024 and a low of $32.0 million during FY2020.
  • In the last 3 years, Adma Biologics' Raw Materials had a median value of $53.0 million in 2023 and averaged $54.0 million.
  • Data for Adma Biologics' Raw Materials shows a peak YoY soared of 32.34% (in 2022) over the last 5 years.
  • Over the past 5 years, Adma Biologics' Raw Materials (Yearly) stood at $32.0 million in 2020, then grew by 14.70% to $36.8 million in 2021, then surged by 32.34% to $48.6 million in 2022, then grew by 8.95% to $53.0 million in 2023, then grew by 14.10% to $60.5 million in 2024.